Linked Life Data

9590392

Source:http://linkedlifedata.com/resource/pubmed/id/9590392

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1998-5-22
pubmed:abstractText
Therapeutic drug monitoring (TDM) for certain tricyclic antidepressants (TCAs) and lithium is supported on the basis of clearly defined therapeutic ranges. TDM is of particular importance in individuals whose pharmacokinetic behavior may differ from that of the general population or is changing as the result of aging and maturation. Once steady-state drug concentrations are achieved, serum or plasma specimens should be collected during the terminal drug-elimination phase and separated from cellular blood components immediately. Methods of analysis must be specific for parent drug and active metabolites and demonstrate imprecision (CVs) within 5-10% over the therapeutic range. For support of overdose situations, semiquantitative values for TCAs and quantitative measures of lithium should be available within 1 h, and routine TDM results should be reported within 24 h of receipt in the laboratory. Standardized and rigorous laboratory practices contribute to improved therapeutic management.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0009-9147
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1073-84
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry.
pubmed:affiliation
Department of Pathology and Laboratory Medicine, University of Louisville, KY 40292, USA. mwlind01@homer.louisville.edu
pubmed:publicationType
Journal Article, Guideline, Review, Practice Guideline